U.S. Pharmaceutical Distribution Giant Acquires Retina Specialty Network

Cencora, Inc. (NYSE: COR) on March 23, 2026 signed a definitive agreement to acquire the retina business of EyeSouth Partners for approximately $1.1 billion (roughly KRW 1.5 trillion). Under the deal, the retina specialists affiliated with EyeSouth will join Cencora’s retina-focused MSO, Retina Consultants of America, and the company expects a modest accretion to adjusted diluted EPS in the first 12 months post-closing. The board reaffirmed its full-year 2026 guidance, noting that although customary closing conditions—including regulatory approvals—are expected to be met, the transaction is not anticipated to close within fiscal 2026.

On February 13, Cencora completed a $3.0 billion senior note offering to repay debt related to its OneOncology acquisition. In its early-February fiscal 2026 first-quarter results, Cencora reported revenue growth, raised its operating income outlook to reflect OneOncology’s contribution, and maintained its EPS guidance. ()

Formerly known as AmerisourceBergen, Cencora is one of the largest pharmaceutical wholesalers and distributors in the U.S. The company rebranded in 2023 and trades on the New York Stock Exchange under the ticker COR. With Retina Consultants of America and the newly integrated EyeSouth retina network, competition continues to intensify among large MSOs consolidating specialized clinics in the U.S. ophthalmology and retina care market. ()